Mark Hallett (National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA) discusses his Review, published in the June issue of The Lancet Neurology, on functional neurological disorder, and talks about new subtypes of this disorder, diagnostic challenges, and how education is important.Read the full article:Functional neurological disorder: new subtypes and shared mechanisms

Eva Feldman (University of Michigan, Ann Arbor, USA) discusses the latest advances in the genetics, risk factors, pathophysiology, therapeutic development, and the diagnosis and prognosis of amyotrophic lateral sclerosis; the Series is published in the May issue of The Lancet Neurology.

Estrella Morenas-Rodriguez and Christian Haass (German Centre for Neurodegenerative Diseases, Munich, Germany) discuss their recent research, published in the April issue of The Lancet Neurology, on soluble TREM2 and its association with Alzheimer’s disease biomarkers and cognition.

John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.Read the full article:Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL)

Giuseppe Citerio (University of Milano-Bicocca, Milan, Italy) discusses the implications of a study from the CENTER-TBI project of the effect of frailty on 6-month outcome after traumatic brain injury, which is published in the February issue of The Lancet Neurology. 

Alberto Costa (Case Western Reserve University, Cleveland, OH, USA) discusses his study on the use of memantine in adolescents and young adults with Down syndrome, which is published in the January issue of The Lancet Neurology.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00369-0/fulltext

Olivier Rascol (Toulouse University, France) discusses the uses of amantadine in the treatment of patients with movement disorders, which are the focus of his Personal View in the December issue of The Lancet Neurology.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00249-0/fulltext

Antonio Uccelli (University of Genoa) discusses his research, published in the November issue of The Lancet Neurology, on the therapeutic use of mesenchymal stem cells for multiple sclerosis.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00301-X/fulltext

Priya Palta (Columbia University, New York) explains the importance of blood pressure control in the prevention of cognitive decline. Her Review, published in the October issue of The Lancet Neurology, provides an update of the mounting evidence that links hypertension with dementia risk.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00248-9/fulltext